Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M. Steinberg MH, et al. Among authors: saunthararajah y. JAMA. 2003 Apr 2;289(13):1645-51. doi: 10.1001/jama.289.13.1645. JAMA. 2003. PMID: 12672732 Clinical Trial.
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.
Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up. Steinberg MH, et al. Am J Hematol. 2010 Jun;85(6):403-8. doi: 10.1002/ajh.21699. Am J Hematol. 2010. PMID: 20513116 Free PMC article. Clinical Trial.
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.
Ataga KI, Smith WR, De Castro LM, Swerdlow P, Saunthararajah Y, Castro O, Vichinsky E, Kutlar A, Orringer EP, Rigdon GC, Stocker JW; ICA-17043-05 Investigators. Ataga KI, et al. Among authors: saunthararajah y. Blood. 2008 Apr 15;111(8):3991-7. doi: 10.1182/blood-2007-08-110098. Epub 2008 Jan 11. Blood. 2008. PMID: 18192510 Free article. Clinical Trial.
A pilot study of subcutaneous decitabine in β-thalassemia intermedia.
Olivieri NF, Saunthararajah Y, Thayalasuthan V, Kwiatkowski J, Ware RE, Kuypers FA, Kim HY, Trachtenberg FL, Vichinsky EP; Thalassemia Clinical Research Network. Olivieri NF, et al. Among authors: saunthararajah y. Blood. 2011 Sep 8;118(10):2708-11. doi: 10.1182/blood-2011-03-341909. Epub 2011 Jun 23. Blood. 2011. PMID: 21700776 Free PMC article.
β-Hemoglobinopathies lead the way.
Saunthararajah Y. Saunthararajah Y. Blood. 2021 Mar 25;137(12):1567-1569. doi: 10.1182/blood.2020009961. Blood. 2021. PMID: 33764430 Free PMC article.
Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies.
Woost PG, William BM, Cooper BW, Ueda Oshima M, Otegbeye F, De Lima MJ, Wald D, Mahfouz RZ, Saunthararajah Y, Stefan T, Jacobberger JW. Woost PG, et al. Among authors: saunthararajah y. Cytometry B Clin Cytom. 2024 Jan;106(1):11-24. doi: 10.1002/cyto.b.22158. Epub 2024 Feb 12. Cytometry B Clin Cytom. 2024. PMID: 38345160
Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy.
Biswas S, Kang K, Ng KP, Radivoyevitch T, Schalper K, Zhang H, Lindner DJ, Thomas A, MacPherson D, Gastman B, Schrump DS, Wong KK, Velcheti V, Saunthararajah Y. Biswas S, et al. Among authors: saunthararajah y. Cell Rep. 2023 Aug 29;42(8):113016. doi: 10.1016/j.celrep.2023.113016. Epub 2023 Aug 18. Cell Rep. 2023. PMID: 37597186 Free PMC article.
162 results